John Hinton, MD
Neurology · Mobile, ALNPI 1982649182
Payments from drug & device makers
Across 381 payments — averaging $708.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$232K
- AbbVie$16K
- UCB Biosciences Inc.$16K
- UCB, Inc.$4K
- Teva Pharmaceuticals USA, Inc.$708
- Novartis$523
- plus $2K from 28 others
Across 1 payment — averaging $2300.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB, Inc.$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 14 | $231,720 |
| AbbVie(2 entities) | 183 | $15,905 |
| UCB Biosciences Inc. | 3 | $15,857 |
| UCB, Inc. | 12 | $3,563 |
| Teva Pharmaceuticals USA, Inc. | 43 | $708 |
| Novartis | 41 | $523 |
| Biogen | 11 | $191 |
| Pfizer | 10 | $172 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $142 |
| Acadia Pharmaceuticals Inc | 6 | $120 |
| Amgen(2 entities) | 6 | $107 |
| Bristol Myers Squibb | 8 | $100 |
| Johnson & Johnson | 5 | $73 |
| Alnylam Pharmaceuticals Inc. | 3 | $70 |
| Lundbeck LLC | 3 | $56 |
| Supernus Pharmaceuticals, Inc. | 3 | $54 |
| EMD Serono, Inc. | 4 | $52 |
| Upsher-smith Laboratories LLC | 3 | $39 |
| CSL Behring | 1 | $38 |
| Eisai Inc. | 2 | $38 |
| Argenx US, Inc. | 1 | $35 |
| E.r. Squibb & Sons, L.L.C. | 3 | $34 |
| Tanabe Pharma America, Inc. | 2 | $31 |
| Catalyst Pharmaceuticals, Inc. | 2 | $29 |
| MDD US Operations, LLC | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| TG Therapeutics, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Octapharma USA, Inc. | 1 | $17 |
| AstraZeneca | 1 | $15 |
| Abbott | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Neurelis, Inc. | 1 | $14 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
How this compares
$269,830 in reported general payments places this provider in the 90th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Mobile
- Daniel DeesMobile$894K
- Hayden LongMobile$386K
- William KilgoMobile$334K
- Charles MarkleMobile$212K
- Bassam BassamMobile$197K
- Dean NaritokuMobile$164K
- Matthew McLeanMobile$113K
- Laura MintoMobile$92K
- Steve CordinaMobile$75K
- Thomas FosterMobile$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.